The Experts below are selected from a list of 516 Experts worldwide ranked by ideXlab platform
Jacques Bonneterre - One of the best experts on this subject based on the ideXlab platform.
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British Journal of Cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of Nasal Septum Perforations have been reported. We report our experience of Nasal Perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings. Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE. Results: Five Nasal Septum Perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg^−1 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m^−2 every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, Nasal Septum Perforation occurred at the time of docetaxel treatment. Conclusion: A high incidence of Nasal Septum Perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British journal of cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
-
Nasal Septum Perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
Journal of Clinical Oncology, 2010Co-Authors: A Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, Jacques BonneterreAbstract:671 Background: Bevacizumab in association with paclitaxel or docetaxel has been approved in patients with metastatic breast cancer. It is currently used in clinical studies in the adjuvant setting. We report our experience of the Nasal Septum Perforation rate in patients receiving bevacizumab together with chemotherapy. Methods: 69 patients were treated with bevacizumab (15 mg/kg every 21 days) and chemotherapy between January 1 and December 31, 2009. An endoNasal tract examination was performed in those experiencing epistaxis, mucosal crusting or Nasal obstruction. Results: Sixty-two patients received bevacizumab in association with taxanes. Fifty-two (75%) had epistaxis and twenty-five had an ENT examination. Six cases of Nasal Septum Perforation were diagnosed (8.7%); all of them had epistaxis and one had a Nasal infection, some experienced turbulent airflow and whistling on inspiration. Four other patients had local symptomatic treatment and are followed by the head and neck surgeon. Four patients wi...
A Mailliez - One of the best experts on this subject based on the ideXlab platform.
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British Journal of Cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of Nasal Septum Perforations have been reported. We report our experience of Nasal Perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings. Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE. Results: Five Nasal Septum Perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg^−1 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m^−2 every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, Nasal Septum Perforation occurred at the time of docetaxel treatment. Conclusion: A high incidence of Nasal Septum Perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British journal of cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
-
Nasal Septum Perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
Journal of Clinical Oncology, 2010Co-Authors: A Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, Jacques BonneterreAbstract:671 Background: Bevacizumab in association with paclitaxel or docetaxel has been approved in patients with metastatic breast cancer. It is currently used in clinical studies in the adjuvant setting. We report our experience of the Nasal Septum Perforation rate in patients receiving bevacizumab together with chemotherapy. Methods: 69 patients were treated with bevacizumab (15 mg/kg every 21 days) and chemotherapy between January 1 and December 31, 2009. An endoNasal tract examination was performed in those experiencing epistaxis, mucosal crusting or Nasal obstruction. Results: Sixty-two patients received bevacizumab in association with taxanes. Fifty-two (75%) had epistaxis and twenty-five had an ENT examination. Six cases of Nasal Septum Perforation were diagnosed (8.7%); all of them had epistaxis and one had a Nasal infection, some experienced turbulent airflow and whistling on inspiration. Four other patients had local symptomatic treatment and are followed by the head and neck surgeon. Four patients wi...
C. Baldini - One of the best experts on this subject based on the ideXlab platform.
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British Journal of Cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of Nasal Septum Perforations have been reported. We report our experience of Nasal Perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings. Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE. Results: Five Nasal Septum Perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg^−1 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m^−2 every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, Nasal Septum Perforation occurred at the time of docetaxel treatment. Conclusion: A high incidence of Nasal Septum Perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British journal of cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
-
Nasal Septum Perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
Journal of Clinical Oncology, 2010Co-Authors: A Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, Jacques BonneterreAbstract:671 Background: Bevacizumab in association with paclitaxel or docetaxel has been approved in patients with metastatic breast cancer. It is currently used in clinical studies in the adjuvant setting. We report our experience of the Nasal Septum Perforation rate in patients receiving bevacizumab together with chemotherapy. Methods: 69 patients were treated with bevacizumab (15 mg/kg every 21 days) and chemotherapy between January 1 and December 31, 2009. An endoNasal tract examination was performed in those experiencing epistaxis, mucosal crusting or Nasal obstruction. Results: Sixty-two patients received bevacizumab in association with taxanes. Fifty-two (75%) had epistaxis and twenty-five had an ENT examination. Six cases of Nasal Septum Perforation were diagnosed (8.7%); all of them had epistaxis and one had a Nasal infection, some experienced turbulent airflow and whistling on inspiration. Four other patients had local symptomatic treatment and are followed by the head and neck surgeon. Four patients wi...
V. Servent - One of the best experts on this subject based on the ideXlab platform.
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British Journal of Cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of Nasal Septum Perforations have been reported. We report our experience of Nasal Perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings. Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE. Results: Five Nasal Septum Perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg^−1 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m^−2 every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, Nasal Septum Perforation occurred at the time of docetaxel treatment. Conclusion: A high incidence of Nasal Septum Perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British journal of cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
-
Nasal Septum Perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
Journal of Clinical Oncology, 2010Co-Authors: A Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, Jacques BonneterreAbstract:671 Background: Bevacizumab in association with paclitaxel or docetaxel has been approved in patients with metastatic breast cancer. It is currently used in clinical studies in the adjuvant setting. We report our experience of the Nasal Septum Perforation rate in patients receiving bevacizumab together with chemotherapy. Methods: 69 patients were treated with bevacizumab (15 mg/kg every 21 days) and chemotherapy between January 1 and December 31, 2009. An endoNasal tract examination was performed in those experiencing epistaxis, mucosal crusting or Nasal obstruction. Results: Sixty-two patients received bevacizumab in association with taxanes. Fifty-two (75%) had epistaxis and twenty-five had an ENT examination. Six cases of Nasal Septum Perforation were diagnosed (8.7%); all of them had epistaxis and one had a Nasal infection, some experienced turbulent airflow and whistling on inspiration. Four other patients had local symptomatic treatment and are followed by the head and neck surgeon. Four patients wi...
Y. Mallet - One of the best experts on this subject based on the ideXlab platform.
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British Journal of Cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of Nasal Septum Perforations have been reported. We report our experience of Nasal Perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings. Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE. Results: Five Nasal Septum Perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg^−1 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m^−2 every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, Nasal Septum Perforation occurred at the time of docetaxel treatment. Conclusion: A high incidence of Nasal Septum Perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).
-
Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
British journal of cancer, 2010Co-Authors: A Mailliez, C. Baldini, J T Van, V. Servent, Y. Mallet, Jacques BonneterreAbstract:Nasal Septum Perforation: a side effect of bevacizumab chemotherapy in breast cancer patients
-
Nasal Septum Perforations: A side effect of the association of bevacizumab and taxanes in patients with breast cancer?
Journal of Clinical Oncology, 2010Co-Authors: A Mailliez, C. Baldini, V. Servent, Y. Mallet, S. Dewas, Jacques BonneterreAbstract:671 Background: Bevacizumab in association with paclitaxel or docetaxel has been approved in patients with metastatic breast cancer. It is currently used in clinical studies in the adjuvant setting. We report our experience of the Nasal Septum Perforation rate in patients receiving bevacizumab together with chemotherapy. Methods: 69 patients were treated with bevacizumab (15 mg/kg every 21 days) and chemotherapy between January 1 and December 31, 2009. An endoNasal tract examination was performed in those experiencing epistaxis, mucosal crusting or Nasal obstruction. Results: Sixty-two patients received bevacizumab in association with taxanes. Fifty-two (75%) had epistaxis and twenty-five had an ENT examination. Six cases of Nasal Septum Perforation were diagnosed (8.7%); all of them had epistaxis and one had a Nasal infection, some experienced turbulent airflow and whistling on inspiration. Four other patients had local symptomatic treatment and are followed by the head and neck surgeon. Four patients wi...
